Table 1.

Clinical features of the Study cohort

LRRK2 genotype	Healthy Controls GG (WT)	Healthy Controls GA (G2019S)	PD patients GG (WT)	PD patients GA (G2019S)
Number	12	14	17	16
Male: Female ratio	4:8	5:9	10:7	10:6
Age at blood draw, mean year +/−SD	62.3 +/− 16.1	53.9 +/− 22.7	64.7 +/− 6.4	70.6 +/− 10.8
Age at onset, mean year +/−SD	N/A	N/A	57.1 +/− 7.8	57.4 +/− 11.5
UPDRS motor, median	1 (0–12)	2 (0–17.5)	17 (5.5–53)	14.5 (1–65)
% definitely on L-DOPA*	N/A	N/A	70.6% (12/17)	81.3% (13/16)

^*L-DOPA status of some patients is not known